Literature DB >> 27370818

Bladder pain induced by prolonged peripheral alpha 1A adrenoceptor stimulation involves the enhancement of transient receptor potential vanilloid 1 activity and an increase of urothelial adenosine triphosphate release.

R Matos1,2,3, J M Cordeiro4, A Coelho1,2,3,5, S Ferreira3, C Silva1,2,5,6, Y Igawa7, F Cruz1,2,5,6, A Charrua1,2,3,5.   

Abstract

AIM: Pathophysiological mechanisms of chronic visceral pain (CVP) are unknown. This study explores the association between the sympathetic system and bladder nociceptors activity by testing the effect of a prolonged adrenergic stimulation on transient receptor potential vanilloid 1 (TRPV1) activity and on urothelial adenosine triphosphate (ATP) release.
METHODS: Female Wistar rats received saline, phenylephrine (PHE), PHE + silodosin, PHE + naftopidil or PHE + prazosin. TRPV1 knockout and wild-type mice received saline or PHE. Visceral pain behaviour tests were performed before and after treatment. Cystometry was performed, during saline and capsaicin infusion. Fos immunoreactivity was assessed in L6 spinal cord segment. Human urothelial ATP release induced by mechanical and thermal stimulation was evaluated.
RESULTS: Subcutaneous, but not intrathecal, PHE administration induced pain, which was reversed by silodosin, a selective alpha 1A adrenoceptor antagonist, but not by naftopidil, a relatively selective antagonist for alpha 1D adrenoceptor. Silodosin also reversed PHE-induced bladder hyperactivity and L6 spinal cord Fos expression. Thus, in subsequent experiments, only silodosin was used. Wild-type, but not TRPV1 knockout, mice exhibited phenylephrine-induced pain. Capsaicin induced a greater increase in voiding contractions in PHE-treated rats than in control animals, and silodosin reversed this effect. When treated with PHE, ATP release from human urothelial cells was enhanced either by mechanical stimulation or by lowering the thermal threshold of urothelial TRPV1, which becomes abnormally responsive at body temperature.
CONCLUSION: This study suggests that the activation of peripheral alpha 1A adrenoceptors induces CVP, probably through its interaction with TRPV1 and ATP release.
© 2016 Scandinavian Physiological Society. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  adenosine triphosphate; adrenoceptors; chronic visceral pain; transient receptor potential vanilloid 1

Mesh:

Substances:

Year:  2016        PMID: 27370818     DOI: 10.1111/apha.12744

Source DB:  PubMed          Journal:  Acta Physiol (Oxf)        ISSN: 1748-1708            Impact factor:   6.311


  5 in total

Review 1.  Preclinical models of endometriosis and interstitial cystitis/bladder pain syndrome: an Innovative Medicines Initiative-PainCare initiative to improve their value for translational research in pelvic pain.

Authors:  Paulina Nunez-Badinez; Bianca De Leo; Alexis Laux-Biehlmann; Anja Hoffmann; Thomas M Zollner; Philippa T K Saunders; Ioannis Simitsidellis; Ana Charrua; Francisco Cruz; Raul Gomez; Miguel Angel Tejada; Stephen B McMahon; Laure Lo Re; Florent Barthas; Katy Vincent; Judy Birch; Jane Meijlink; Lone Hummelshoj; Patrick J Sweeney; J Douglas Armstrong; Rolf-Detlef Treede; Jens Nagel
Journal:  Pain       Date:  2021-09-01       Impact factor: 6.961

2.  The water avoidance stress induces bladder pain due to a prolonged alpha1A adrenoceptor stimulation.

Authors:  Rita Matos; Paula Serrão; Larissa Rodriguez; Lori Ann Birder; Francisco Cruz; Ana Charrua
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-05-31       Impact factor: 3.000

Review 3.  Current Pharmacologic Approaches in Painful Bladder Research: An Update.

Authors:  Karl-Erik Andersson; Lori Birder
Journal:  Int Neurourol J       Date:  2017-12-31       Impact factor: 2.835

4.  Silodosin Improves Pain and Urinary Frequency in Bladder Pain Syndrome/Interstitial Cystitis Patients.

Authors:  Pedro Abreu-Mendes; Beatriz Araújo-Silva; Ana Charrua; Francisco Cruz; Rui Pinto
Journal:  J Clin Med       Date:  2022-09-26       Impact factor: 4.964

Review 5.  Animal Modelling of Interstitial Cystitis/Bladder Pain Syndrome.

Authors:  Lori Birder; Karl-Erik Andersson
Journal:  Int Neurourol J       Date:  2018-01-31       Impact factor: 2.835

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.